Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - BRL | - |
|
| 05-21 | Brazil's GPA sells stake in Stix for 23 million reais, ends joint venture | RE |
| 05-06 | Raia Drogasil S.A., Q1 2026 Earnings Call, May 06, 2026 |
| Market Cap | 28.94B 5.6B 4.88B 4.49B 4.23B 7.91B 527B 7.96B 53.47B 20.77B 260B 21B 20.55B 901B | P/E 2026 * |
18.8x | P/E 2027 * | 13.9x |
|---|---|---|---|---|---|
| Enterprise Value | 36.95B 7.14B 6.23B 5.74B 5.4B 10.1B 673B 10.17B 68.27B 26.51B 332B 26.82B 26.24B 1,150B | EV / Sales 2026 * |
0.81x | EV / Sales 2027 * | 0.71x |
| Free-Float |
73.5% | Yield 2026 * |
2.19% | Yield 2027 * | 2.98% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
Renato Raduan
CEO | Chief Executive Officer | 50 | 01/01/2025 |
| Director of Finance/CFO | 63 | 29/04/2013 | |
| Chief Tech/Sci/R&D Officer | - | 01/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 24/11/2011 | |
| Director/Board Member | 74 | 29/04/2013 | |
| Director/Board Member | 72 | 24/11/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.64% | -3.95% | +1.19% | +9.13% | 1.2B | |
| -1.07% | -2.42% | +0.92% | +6.30% | 438M | |
| -0.11% | -0.70% | +8.50% | +24.71% | 62.76M | |
| Average | -0.61% | -3.74% | +3.54% | +13.38% | 566.11M | |
| Weighted average by Cap. | -0.73% | -6.33% | +1.39% | +8.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.7B 8.84B 7.7B 7.1B 6.68B 12.49B 833B 12.58B 84.45B 32.8B 410B 33.17B 32.46B 1,423B | 53.11B 10.27B 8.95B 8.25B 7.76B 14.51B 968B 14.62B 98.13B 38.11B 477B 38.55B 37.72B 1,653B |
| Net income | 1.58B 306M 267M 246M 231M 432M 28.84B 435M 2.92B 1.14B 14.21B 1.15B 1.12B 49.25B | 2.13B 413M 360M 331M 312M 583M 38.89B 587M 3.94B 1.53B 19.16B 1.55B 1.52B 66.43B |
| Net Debt | 8.01B 1.55B 1.35B 1.24B 1.17B 2.19B 146B 2.2B 14.8B 5.75B 71.94B 5.81B 5.69B 249B | 8.74B 1.69B 1.47B 1.36B 1.28B 2.39B 159B 2.41B 16.15B 6.27B 78.51B 6.34B 6.21B 272B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Select your edition
All financial news and data tailored to specific country editions
